Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University

Drug Profile

Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University

Alternative Names: ABI-H2158; Antiviral therapeutics - Assembly Biosciences; Core Protein Allosteric Modulators; CpAMs

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences; Indiana University
  • Class Small molecules
  • Mechanism of Action Viral core protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 25 Sep 2017 Assembly Biosciences plans a phase Ia trial for Hepatitis B infection
  • 13 Apr 2016 Pharmacodynamic and pharmacokinetic data presented at the International Liver Congress (ILC-2016) ,
  • 11 Jul 2014 Ventrus Biosciences has merged with Assembly Pharmaceuticals to form Assembly Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top